Ageing biology, telomere research, retinal research
Human evidence
Older regional human evidence includes a 162-patient retinitis-pigmentosa study using a highly specific parabulbar route. Modern 2025 telomere findings are in cultured human cells, not a longevity trial. No large independent human lifespan trial was identified.
Regulatory status
Not FDA-approved; compounded-use safety information is insufficient.
Main limitations
Human lifespan extension, systemic anti-ageing benefit, general sleep benefit, long-term systemic safety or a validated longevity regimen.
Safety
Modern human safety and efficacy datasets are inadequate; FDA lists lack of safety information for compounded epitalon.
i
Older regional human evidence includes a 162-patient retinitis-pigmentosa study using a highly specific parabulbar route. Modern 2025 telomere findings are in cultured human cells, not a longevity trial. No large independent human lifespan trial was identified.
What the evidence actually supports
✓Publish as historical ophthalmic evidence only.
✓Keep synthetic Epitalon separate from Epithalamin and label lifespan claims unproven.
✓Use as mechanistic evidence with an explicit translation/safety caution.
What is not established / key limitations
×Study age, regional reporting and indication-specific route limit generalizability.
×Human longevity claims are often mixed with Epithalamin/pineal-extract literature, which is not the same product.
×Cell-line effects do not establish anti-ageing benefit and may have different implications in cancer cells.
Selected study & evidence records
Epitalon in retinitis pigmentosa
2002 · Older clinical study · n=162
The publication reported a positive clinical effect in approximately 90% of treated cases.
Modern human safety and efficacy datasets are inadequate; FDA lists lack of safety information for compounded epitalon.
Systemic long-term human safety is not established; telomere/telomerase effects require careful interpretation, especially because cancer-cell models can respond differently.
Technical details
Mechanism / biologyInvestigated for gene-expression, telomerase/telomere and pineal/retinal biology.
Route / formulation boundaryDo not confuse Epitalon (tetrapeptide) with Epithalamin (pineal extract) when citing older literature.
Identity / data-quality noteSynthetic Epitalon must not be conflated with Epithalamin/pineal extract studies.
Dosing evidence statusVerified historical human retinal-study exposure added. A historical retinitis-pigmentosa study used 5.0 µg per eye by parabulbar injection for 10 consecutive days. That study exposure does not establish a general systemic or longevity dose.
Identifiers & alternate namesEpithalon
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
